Completion of Venco Acquisition in Londrina Brazil

RNS Number : 7531K

Dechra Pharmaceuticals PLC

18 December 2018

 

Tuesday, 18 December 2018

Dechra^® Pharmaceuticals PLC

(Dechra, Group, Company)

Acquisition Completion

Dechra secures access to rapidly growing South American markets

Further to the announcement on 19 October 2018, Dechra is pleased to announce the completion of the acquisition of the entire share capital of Laboratorios Vencofarma do Brasil Ltda (Venco, acquisition), based in Londrina Brazil.

Venco has a large portfolio of Vaccines and other Food producing Animal Products (FAP) which it sells predominantly within Brazil, with a small but increasing presence in other South American and international markets. It also has a small range of Companion Animal Products (CAP) vaccines and pharmaceuticals, which are sold mainly on the Brazilian market. Overall it has over 200 current product registrations. Brazil is the fourth biggest FAP market in the world, and Vaccines is the fastest growing therapeutic area within FAP globally.

The acquisition provides Dechra with a strategically significant presence within the rapidly growing Brazilian and South American markets. Dechra will invest significantly over the next 2 to 3 years to develop the business and its presence in South America, will continue to develop the existing Venco pipeline and registrations, register relevant Dechra products and establish the Dechra brand in the region.

Ian Page, Dechra's Chief Executive Officer commented, "We are delighted to complete on the Venco acquisition, enabling Dechra to establish a key new footprint in the rapidly expanding South American markets. We are pleased to welcome the Venco team to Dechra, to begin the integration process and our additional investment in this rapidly growing market."

Dechra will announce a Trading Update covering the six month period to 31 December 2018 on Monday 14 January 2019.

Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer	Office:  [phone]
Richard Cotton, Chief Financial Officer e-mail: [e-mail]	Office:  [phone]
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail: [e-mail]	Mobile: [phone] Office:  [phone]

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.  Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. 

For more information, please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document may contain certain forward-looking statements.  The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document.  By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty.  Therefore, nothing in this document should be construed as a profit forecast by the Company.

 

END

 

 

ACQDBBDDCXBBGIR